U
KBIO

UBS’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

UBS’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$3K Sell
274
-444
-62% -$6.12K ﹤0.01% 9940
2014
Q2 		$13K Buy
+718
New +$12.3K ﹤0.01% 8667
2013
Q4 		– Sell
-148
Closed -$5K – 11481
2013
Q3 		$5K Buy
148
+18
+14% +$820 ﹤0.01% 9520
2013
Q2 		$6K Buy
+130
New +$5.89K ﹤0.01% 9211

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIM
SSI Investment Management Los Angeles, California $1.45B AUM 5.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UBS's KBIO Position: Q3 2014 in Review

UBS reduced its KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) stake by 62% in Q3 2014, selling an estimated $6.12K and leaving 274 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #9940.

UBS first reported a position in KBIO in Q2 2013 and has held it in 4 quarters since. The position peaked at $13K in Q2 2014. 35 funds tracked by Wall St. Rank hold KBIO as of Q3 2014.

  • UBS held 274 shares of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) worth $3K as of Q3 2014.
  • UBS sold 444 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q3 2014, an estimated $6.12K.
  • KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9940 holding.
  • UBS first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and has held it in 4 quarters since.
  • UBS's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $13K in Q2 2014.
  • 35 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.